- Marker Therapeutics Inc MRKR received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT).
- The CPRIT award is intended to support the adjuvant arm Phase 2 trial of its MultiTAA-specific T cell product MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant.
- The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival compared with a randomized control group.
- Price Action: MRKR shares are up are 15.50% at $1.94 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareFinancingMoversTrading IdeasGeneralacute myeloid leukemiaBriefsPhase 2
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
